Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: N05CD14

Byfavo(remimazolam besilate)

Conscious Sedation

Marketing Authorisation Holder: Paion Pharma GmbH

EMA Authorisation: 26/03/2021

INN: remimazolam

Indication

Remimazolam is indicated in adults for procedural sedation. Remimazolam 50 mg is indicated in adults for intravenous induction and maintenance of general anaesthesia.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Byfavo — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.